LBODP081 The Relationship Between Body Mass Index Changes And Bone Age Progression During Gonadotropin-releasing Hormone Agonist Treatment In Girls With Idiopathic Central Precocious Puberty

PURPOSE: To analyze the relationship between body mass index change and bone age progression during gonadotropin-releasing hormone agonist(GnRHa) treatment in girls with idiopathic central precocious puberty Methods: 65 girls with idiopathic central precocious puberty who are treated with GnRHa more than 2 years were retrospectively reviewed. Height, weight, Tanner stage, bone age were measured every 6 months from the start of treatment. The degree of obesity was evaluated using the body mass index (BMI) standard deviation score (SDS), and the relationship between the change in obesity and the progression of bone age was analyzed. Overweight was defined as a BMI greater than or equal to the 85th percentile. The chronological age at the start and the end of treatment was 7. 00±0. 00 years and 10.63±0.50 years in the overweight group (16 patients), and 6.86±0.35 years and 10.71±0.54 years in the other group (49 patients), respectively. RESULTS: There was no difference in bone age between the normal weight group and the overweight group at the start of treatment (9.85±0.57 years vs 10. 04±0.73 years, P=0.263). Bone age was higher in the overweight group, but after 1 year of treatment, 2 years of treatment, and at the end of treatment, the overweight group had a higher bone age than the normal weight group (10.47±0.56 years vs 10.87±0.57 years, P=0. 02; 11. 06±0.47 years vs 11.46±0.51 years, P=0. 004; 11.70±0.46 years vs 12. 01±0.52 years, P=0. 03). Bone age at the end of treatment was related to overweight at the start of treatment (r=0.265, P=0. 03) and the increase in BMI SDS from normal to overweight during treatment (r=0.285, P=0. 02). There were 11 children (17%) whose BMI SDS increased from normal to overweight during treatment, compared with the other patients, there was no difference in bone age during 2 years of treatment, but bone age at the end of treatment was higher (12. 09±0.60 years vs 11.71±0.47 years, P=0. 02), and the difference in bone age before and after treatment was also greater (2.31±0.68 years vs 1.79±0.52 years, P=0. 01). Linear regression analysis demonstrated that the increase in BMI SDS from normal to overweight during treatment had a positive correlation with bone age at the end of treatment (β=0.31, R2=0. 07, P=0. 03). CONCLUSION: In girls with central precocious puberty, an increase in obesity from normal to overweight during GnRHa treatment does not affect bone age progression until 2 years from the start of treatment, but might be a risk factor for bone age progression at the end of treatment. Presentation: No date and time listed